Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
2 hours ago
2
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.